Effect of monoclonal antibodies to PCSK9 on high‐sensitivity C‐reactive protein levels: a meta‐analysis of 16 randomized controlled treatment arms

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging class of low‐density lipoprotein cholesterol (LDL‐C)‐lowering agents. In spite of their known effects on lipids, the impact of these drugs on systemic inflammation is less known. We aimed to investigate the effect...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Clin Pharmacol
Prif Awduron: Sahebkar, Amirhossein, Di Giosia, Paolo, Stamerra, Cosimo Andrea, Grassi, Davide, Pedone, Claudio, Ferretti, Gianna, Bacchetti, Tiziana, Ferri, Claudio, Giorgini, Paolo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2016
Pynciau:
Meta‐analysis
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876179/
https://ncbi.nlm.nih.gov/pubmed/26861255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12905
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg